The DOI matches its Crossref record; 312 of the 314 references it cites were found in a registry or an index.
Alzheimer's Disease: From Pathology to Therapeutic Approaches
Abstract
Mind how you go: The current strategies for the development of therapies for Alzheimer's disease are very diverse. Particular attention is given to the search for inhibitors (see picture for two examples) of the proteolytic enzyme beta- and gamma-secretase, which inhibits the cleavage of the amyloid precursor proteins into amyloid beta peptides, from which the disease-defining deposits of plaque in the brains of Alzheimer's patients originates.Research on senile dementia and Alzheimer's disease covers an extremely broad range of scientific activities. At the recent international meeting of the Alzheimer's Association (ICAD 2008, Chicago) more than 2200 individual scientific contributions were presented. The aim of this Review is to give an overview of the field and to outline its main areas, starting from behavioral abnormalities and visible pathological findings and then focusing on the molecular details of the pathology. The "amyloid hypothesis" of Alzheimer's disease is given particular attention, since the majority of the ongoing therapeutic approaches are based on its theoretical framework.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, use of non-specific chelators (i.e., CQ) that do not interact selectively with the Aβ–metal species exhibit adverse side effects that will likely limit their long term clinical use.3,28,29,31,44,46–48”
From Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide (2012) · cites this paper as [3]
In the citing paper
“as well as lead to formation of reactive oxygen species (ROS) and oxidative stress.3,26–31,33–36”
From Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide (2012) · cites this paper as [3]
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Gauthier, S. G., Reisberg, ., Zaudig, M., Petersen, R. C., Ritchie, K. A., Broich, K., Belleville, S., Brodaty, H., Bennett, D. A., Chertkow, H. M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 4,094
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
Research works printed but not linked: 11
- Stokin G. B., 2006, J. Physiol., 99, 193
- Younkin S. G., 1986, Fed. Proc., 45, 2982
- Cras P., 1990, Am. J. Pathol., 137, 241
- Yamaguchi H., 1992, Am. J. Pathol., 141, 249
- Tanzi R. E., 2004, Neuron, 43, 605
- Gandy S., 2005, J. Clin. Invest., 115, 1121
- Higgins G. A., 2003, Behav. Pharmacol., 14, 419
- 10.1124/jpet.105.100271 · DOI
- Pissarnitski D., 2007, Curr. Opin. Drug Discovery Dev., 10, 392
- Hills I. D., 2007, Curr. Opin. Drug Discovery Dev., 10, 383
- Durham T. B., 2006, Curr. Opin. Drug Discovery Dev., 9, 776
Cited by
Sorted by citations
Oxidative stress and the amyloid beta peptide in Alzheimer’s disease
Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018) · Redox Biology · doi:10.1016/j.redox.2017.10.014 · Cited by 2,185
Compromised MAPK signaling in human diseases: an update
Kim, E., & Choi, E. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1472-2 · Cited by 1,033
Bioinorganic Chemistry of Alzheimer’s Disease
Kepp, K. P. (2012) · Chemical Reviews · doi:10.1021/cr300009x · Cited by 683
Mitochondria-Targeting Ceria Nanoparticles as Antioxidants for Alzheimer’s Disease
Kwon, H. J., Cha, M.-Y., Kim, D., Kim, D., Soh, M., Shin, K., Hyeon, T., & Mook‐Jung, I. (2016) · ACS Nano · doi:10.1021/acsnano.5b08045 · Cited by 667
New Horizons for Diagnostics and Therapeutic Applications of Graphene and Graphene Oxide
Feng, L., Wu, L. J., & Qu, X. (2012) · Advanced Materials · doi:10.1002/adma.201203229 · Cited by 634
Metadata
- Authors
- Jakob‐Roetne, R., & Jacobsen, H.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- Corresponding author
- Jakob‐Roetne, Roland
- Jacobsen, Helmut
- ORCID
- Jacobsen, Helmut
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2009-04-07
- Volume
- 48
- Issue
- 17
- Pages
- 3030-3059
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W2065100984
- Cited by
- 626
- References
- 314
- Citations by year
- 2026: 21 · 2025: 19 · 2024: 27 · 2023: 26 · 2022: 39 · 2021: 27 · 2020: 38 · 2019: 37 · 2018: 39 · 2017: 49 · 2016: 40 · 2015: 52 · 2014: 45 · 2013: 45 · 2012: 43
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Angewandte Chemie International Edition (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, amyloid hypothesis, beta-secretase inhibitors, gamma-secretase inhibitors, amyloid precursor protein, amyloid-beta, amyloid plaques, behavioral abnormalities, Alzheimer's disease pathology, Alzheimer's disease therapeutics
- MeSH terms
- Alzheimer Disease, Amyloid, Humans, Protease Inhibitors, Amyloid Precursor Protein Secretases, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
